Page last updated: 2024-08-21

pyrazines and Pituitary Neoplasms

pyrazines has been researched along with Pituitary Neoplasms in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Graw, J; Lee, M; Pellegata, NS; Roncaroli, F; Theodoropoulou, M; Zatelli, MC	1
Casanueva, FF; Cordido, F; de Vries, WR; Dieguez, C; Koppeschaar, HP; van Dam, PS; van Thiel, E; Veldhuyzen, BF	1
Casanueva, FF; Cordido, F; Dieguez, C; Martinez, T; Peñalva, A	1

Trials

2 trial(s) available for pyrazines and Pituitary Neoplasms

Article	Year
Diagnosis of growth hormone deficiency after pituitary surgery: the combined acipimox/GH-releasing hormone test. Clinical endocrinology, 2003, Volume: 58, Issue:2 Topics: Adenoma; Adolescent; Adult; Aged; Area Under Curve; Arginine; Fatty Acids, Nonesterified; Female; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Insulin; Male; Middle Aged; Pituitary Neoplasms; Predictive Value of Tests; Pyrazines; Stimulation, Chemical	2003
Effect of acute pharmacological modulation of plasma free fatty acids on GH secretion in acromegalic patients. Clinical endocrinology, 2001, Volume: 54, Issue:4 Topics: Acromegaly; Adenoma; Area Under Curve; Fatty Acids, Nonesterified; Feedback; Female; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Male; Middle Aged; Niacin; Pituitary Neoplasms; Pyrazines; Statistics, Nonparametric	2001

Article

Year

Diagnosis of growth hormone deficiency after pituitary surgery: the combined acipimox/GH-releasing hormone test.

Clinical endocrinology, 2003, Volume: 58, Issue:2

Topics: Adenoma; Adolescent; Adult; Aged; Area Under Curve; Arginine; Fatty Acids, Nonesterified; Female; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Insulin; Male; Middle Aged; Pituitary Neoplasms; Predictive Value of Tests; Pyrazines; Stimulation, Chemical

2003

Effect of acute pharmacological modulation of plasma free fatty acids on GH secretion in acromegalic patients.

Clinical endocrinology, 2001, Volume: 54, Issue:4

Topics: Acromegaly; Adenoma; Area Under Curve; Fatty Acids, Nonesterified; Feedback; Female; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Male; Middle Aged; Niacin; Pituitary Neoplasms; Pyrazines; Statistics, Nonparametric

2001

Other Studies

1 other study(ies) available for pyrazines and Pituitary Neoplasms

Article	Year
Levels of p27 sensitize to dual PI3K/mTOR inhibition. Molecular cancer therapeutics, 2011, Volume: 10, Issue:8 Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Disease Models, Animal; Drug Synergism; Gene Expression Regulation, Neoplastic; Mice; Multiple Endocrine Neoplasia; Phosphoinositide-3 Kinase Inhibitors; Pituitary Neoplasms; Proteasome Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Rats; Signal Transduction; TOR Serine-Threonine Kinases	2011

Article

Year

Levels of p27 sensitize to dual PI3K/mTOR inhibition.

Molecular cancer therapeutics, 2011, Volume: 10, Issue:8

Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Disease Models, Animal; Drug Synergism; Gene Expression Regulation, Neoplastic; Mice; Multiple Endocrine Neoplasia; Phosphoinositide-3 Kinase Inhibitors; Pituitary Neoplasms; Proteasome Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Rats; Signal Transduction; TOR Serine-Threonine Kinases

2011